20:30 – 21:30
Pharming Symposium (not part of CME programme)
Title: “Diagnosis, management, and recent advances in the treatment of Activated phosphoinositide 3-kinase δ syndrome (APDS), a rare genetic primary immunodeficiency disorder”
Rationale: Activated phosphoinositide 3-kinase δ syndrome (APDS) is a rare, combined immune deficiency (CID), which presents clinicians with many diagnostic and management challenges. It has few signs and symptoms that clearly differentiate it from other CIDs and current management options are often aimed at treating symptoms as they present. In this symposium we will discuss the advances made in understanding this condition through the ESID APDS registry and the diagnostic and treatment challenges of APDS as experienced by an expert in the field. Following this we present the latest PhIII clinical data on leniolisib, a selective oral PI3Kδ inhibitor in development for APDS treatment. This symposium will be of interest to all those working in the field of primary immune deficiencies.
Chair: Prof Stephan Ehl, MD, Ph.D – Institute for Immunodeficiency, Freiburg
- Challenges with diagnosis and management of APDS – Dr Anita Chandra, MD, Ph.D – Cambridge University Hospitals/University of Cambridge
- Leniolisib: safety and efficacy results from Phase 3 clinical trial – Prof Anna Sediva, MD, Ph.D – Charles University, Prague